Takeda Pharmaceutical Company Limited

Lexicon Pharmaceuticals, Inc.

Curagen Corporation

Amgen Fremont Inc.

Celldex Therapeutics Limited

Gregory M Landes

Mary Haak-Frendscho

Vinay Bhaskar

Kathleen Ann Elias

Wouter Korver

Andrew Walling Drake

Shweta Singh

Gyorgy Pal Snell

Seokjoo Hong

David Reed Powell

E-Chiang Lee

Urvi Desai

Xiao Feng

Ling Chen

Kyu Chung

Ian Nevin Foltz

Erin Willert

Peter S Mezes

Francine Zhifen Chen

Michael Jeffers

Binyam Bezabeh

Kam Fai Tse

Nikolia Khramtsov

Gary Starling

Mehdi Mesri

David George Potter

Shewta Singh

Robert Joseph Brommage, Jr

Jeff Liu

Francine Chen

Kam Fei Tse

Provided in this disclosure are anti-CD38 binding domains, a composition comprising the anti-CD38 binding domains, nucleic acids encoding the anti-CD38 binding domains, and a method of using the anti-CD38 binding domains or the composition for treating multiple myeloma.

Anti-CD38 binding domains

Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.

Anti-CD38 antibodies

Antibodies that neutralize Notum Pectinacetylesterase are described, as well as compositions comprising them, and methods of their use to treat diseases and disorders affecting the bone.

Antibodies that bind Notum Pectinacetylesterase

Conjugated anti-CD38 antibodies

The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof

Monoclonal antibodies that specifically bind to ANGPTL3 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL3 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.

Monoclonal antibodies against ANGPTL3

Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.

Monoclonal antibodies against ANGPTL4

Growing community of inventors

The Woodlands, TX, United States of America

Gregory M Landes